Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, ...

An immune system defect makes affected individuals vulnerable to severe viral diseases such as influenza or COVID-19. It is ...

A total of 9% of placebo recipients contracted COVID-19 from a household member, compared with 3% of ensitrelvir recipients, ...

Preclinical and Phase 1 data suggest that ratutrelvir can be used without ritonavir and may reduce the likelihood of COVID rebound and the risk ...

UVA School of Medicine emeritus professor Dr. Frederick G. Hayden helped design the trial and presented the results Wednesday ...

But what if you could avoid getting COVID-19 altogether? That’s the potential promise of a new study on a drug made by ...

Uninfected people who began taking the antiviral within 72 hours of symptoms first appearing in a household member were ...

The lack of available medications in the United States for COVID post-exposure prophylaxis leaves household members in close ...

Tivoxavir marboxil (TXM), administered as a single dose in non-human primates, significantly reduced lung viremia and prevented weight loss, two ...

The COVID-19 pandemic took hold across the globe 5 years ago this month. The Conversation talked to Former Former East-West ...

The results mean that the drug lowered the risk of getting COVID-19 by 67%. The idea of using an antiviral treatment to protect people at high risk of infection isn’t new. The popular flu ...